<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234403</url>
  </required_header>
  <id_info>
    <org_study_id>1839IL/0141</org_study_id>
    <nct_id>NCT00234403</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Combination of Iressa &amp; Faslodex® in Patients With Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients With Advanced or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose
      of fulvestrant 250 mg im once a month will be evaluated in female patients with
      histologically-confirmed advanced or metastatic, ER and/or PR positive breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the progression-free survival (PFS) of the combination of 250 mg ZD1839 and fulvestrant in patients with advanced or metastatic breast cancer</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the objective response rate (complete response [CR] and partial response [PR]) at trial closure.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the disease control rate at trial closure.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate overall survival.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety &amp; tolerability of the combination gefitinib and fulvestrant</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib and fulvestrant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed advanced or metastatic breast cancer

          -  postmenopausal females with amenorrhoea &gt; 12 months and an intact uterus

          -  FSH levels within postmenopausal range or have undergone a bilateral oophorectomy

          -  ER &amp;/or PR positive

          -  previous adjuvant hormone therapy &gt; 12 months prior to enrolment

          -  previous adjuvant chemotherapy &gt; 6 months prior to enrolment

          -  measurable disease according to RECIST and/or non measurable bone disease

          -  life expectancy of at least 12 weeks

          -  World Health Organisation (WHO) performance status (PS) of 0 to 1.

        Exclusion Criteria:

          -  Male

          -  life-threatening metastatic visceral disease

          -  evidence of clinically active interstitial lung disease

          -  ER and PR negative

          -  treatment with LHRH analogues &lt; 3 months prior to enrolment

          -  patients who have restarted menses or do not have FSH levels within the postmenopausal
             range

          -  treatment with strontium - 90 (or other radio pharmaceutical) within the previous 3
             months

          -  Treatment with hormonotherapy and/or chemotherapy for advanced disease

          -  extensive radiotherapy to measurable lesions within the last 4 weeks (i.e. &gt;30% of
             bone marrow, e.g. whole of pelvis or half of spine)

          -  currently receiving oestrogen replacement therapy

          -  treatment with a non-approved or experimental drug within 4 weeks before enrolment

          -  absolute neutrophil count (ANC) less than 1.5 x 109/litre (L) or platelets less than
             100 x 109/L , serum bilirubin greater than 1.25 times the upper limit of reference
             range (ULRR, serum creatinine greater than 1.5 mg/dL, alanine aminotransferase (ALT)
             or aspartate aminotransferase (AST) greater than 2.5 times the ULRR if no demonstrable
             liver metastases, or greater than 5 times the ULRR in the presence of liver
             metastases, history of bleeding diathesis or long term or present anticoagulant
             therapy (other than antiplatelet therapy

          -  any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer
             therapy

          -  concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, known

          -  severe hypersensitivity to ZD1839 or fulvestrant or any of the excipients of this
             product.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Spain Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Gerona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Jaen</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2005</study_first_submitted>
  <study_first_submitted_qc>October 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2005</study_first_posted>
  <last_update_submitted>April 22, 2009</last_update_submitted>
  <last_update_submitted_qc>April 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2009</last_update_posted>
  <keyword>Advanced breast cancer</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>ER positive breast cancer</keyword>
  <keyword>PR positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

